Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Financing channel feed
BioNTech expects up to $950M in Covid vaccine write-offs after Pfizer lowers expectations
Last year
Coronavirus
HHS selects intranasal vaccine candidates for Project NextGen, doles out $500M in funds
Last year
#EuroBio23: The downturn, taking risks and the ‘biotech mafia’
Last year
People
Deals
Astria nabs preclinical OX40 atopic dermatitis drug for $15M upfront, prices $64M offering
Last year
Deals
Exclusive: Liquid-biopsy startup closes $17M to fund ovarian cancer diagnostic test
Last year
Diagnostics
Pharma-backed MinervaX raises €54M as it aims to move its group B Streptococcus vaccine into PhIII
Last year
Agomab draws $100M for fibrosis pipeline, adding to drumbeat of nine-figure Series C rounds
Last year
Startups
Exclusive: Andreessen Horowitz-backed startup is using AI to design lipid nanoparticles that go beyond the liver
Last year
Return of the megaround: Main Street Health raises $315M for value-based care: #HLTH23
Last year
Health Tech
Novartis, Bristol Myers back $61M Series A raise for dementia biotech AstronauTx
Last year
Startups
Antimicrobial resistance biotech secures $37M with ex-CureVac CEO Franz-Werner Haas at the helm
Last year
BMS-backed liquid biopsy biotech Precede Biosciences debuts to enhance precision medicine approaches
Last year
Startups
Diagnostics
AI-driven biotech Iambic snags $100M to enter the clinic next year in HER2 field
Last year
Startups
AI
Exclusive: Dimension leads $40M round for lab automation company Automata Technologies
Last year
Lexeo Therapeutics and Abivax seek Nasdaq listings in shrinking pre-Thanksgiving window for biotech IPOs
Last year
Madrigal raises $500M for NASH drug launch, discloses cyberattack
Last year
With its ex-Novartis cancer drug near the finish line, Adlai Nortye raises $97.5M in Nasdaq debut
Last year
Scoop: Led by former Trump official, Altesa BioSciences raises $35M for antivirals, recruits Moncef Slaoui to board
Last year
People
Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025
Last year
Diagnostics
Chicago AI drug discovery shop Evozyne nabs $81M in bid to make new proteins
Last year
Exclusive: CellFE raises $22M Series A to advance a new cell therapy manufacturing idea
Last year
Cell/Gene Tx
Manufacturing
Avalyn raises $175M to test inhaler versions of IPF medicines in PhII trials
Last year
Forcefield Therapeutics to start £35M Series A in October after scooping ex-Novartis exec John Tsai as new CEO
Last year
People
Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms
Last year
Startups
In Focus
First page
Previous page
25
26
27
28
29
30
31
Next page
Last page